The glutamine metabolism genes, including ME1 and GOT1, were identified as novel indicators for NSCLC radioresistance and predictive biomarkers in the radiation treatment of NSCLC [14]. The gene discussed is GOT1; the disease is non-small cell lung carcinoma.